Effect of Ostracism and General Education on Career Development under Mediation of Personality: A Study of Religious Schools in Pakistan

How ostracism affects personality and career development of the students in recognized religious schools (Madrassas) in Pakistan? How general education averts ostracism and improves personality and career development in Madrassas? How all these variables are associated? It was significant finding answers to these questions as yet in literature the mentioned variables are considered separate constructs whereas this study observed them interplaying in 4 recognized Madrassas. The study collected data from a simple random sample of size 280 protégés using reliable and valid instrument. Data analyses were conducted using Pearson’s correlation, regression and mediation test. Ostracism played positive role both on personality and career development while general education was lagging behind against expectation. Study recommended rational improvements, direction for future research expressing its limitations

Personality Mediated Career Development under Islamic Work Ethics in Pakistani Religious Schools

Religious schools known as Madrassas in Pakistan contribute significant human resource development (HRD) to the society enabling career development (CD) of protégés under Islamic work ethics (IWE). Yet the impact of IWE on CD and protégés’ personalities in recognized and well reputed Madrassas need elaboration. This study hypothesized that personality mediates the relationship between IWE and CD. It collected data employing stratified random sampling for 280 final year protégés in the Madrassas from Lahore, Pakistan. Data was analyzed using Pearson’s correlation, linear regression and Baron and Kenny test. Results confirmed full mediation of personality among IWE and CD and also the direct correlation of IWE as a significant determinant of CD in the selected context. While results of this study remained akin to various studies describing CD for business organizations it contributed value adding role of IWE in CD of religious human resource

Personality Mediated Career Development under Islamic Work Ethics in Pakistani Religious Schools

Religious schools known as Madrassas in Pakistan contribute significant human resource development (HRD) to the society enabling career development (CD) of protégés under Islamic work ethics (IWE). Yet the impact of IWE on CD and protégés’ personalities in recognized and well reputed Madrassas need elaboration. This study hypothesized that personality mediates the relationship between IWE and CD. It collected data employing stratified random sampling for 280 final year protégés in the Madrassas from Lahore, Pakistan. Data was analyzed using Pearson’s correlation, linear regression and Baron and Kenny test. Results confirmed full mediation of personality among IWE and CD and also the direct correlation of IWE as a significant determinant of CD in the selected context. While results of this study remained akin to various studies describing CD for business organizations it contributed value adding role of IWE in CD of religious human resource

Effect of Ostracism and General Education on Career Development under Mediation of Personality: A Study of Religious Schools in Pakistan

How ostracism affects personality and career development of the students in recognized religious schools (Madrassas) in Pakistan? How general education averts ostracism and improves personality and career development in Madrassas? How all these variables are associated? It was significant finding answers to these questions as yet in literature the mentioned variables are considered separate constructs whereas this study observed them interplaying in 4 recognized Madrassas. The study collected data from a simple random sample of size 280 protégés using reliable and valid instrument. Data analyses were conducted using Pearson’s correlation, regression and mediation test. Ostracism played positive role both on personality and career development while general education was lagging behind against expectation. Study recommended rational improvements, direction for future research expressing its limitations

A Concurrence Study on Interoperability Issues in IoT and Decision Making Based Model on Data and Services being used during Inter-Operability

The Internet-of-Things (IoT) has become an important topic among researchers owing to its potential to change the way we live and use smart devices. In recent years, many research work found in the world are interrelated and convey via the existing web structure which makes a worldwide system called IoT. This study focused on the significant improvement of answers for a wider scope of gadgets and the Internet of Things IoT stages in recent years. In any case, each arrangement gives its very own IoT framework, gadgets, APIs, and information configurations promoting interoperability issues. These issues are the outcome of numerous basic issues, difficulty to create IoT application uncovering cross-stage, and additionally cross-space, trouble in connecting non-interoperable IoT gadgets to various IoT stages, what's more, eventually averts the development of IoT innovation at an enormous scale. To authorize consistent data sharing between various IoT vendors, endeavors by a few academia, industrial, and institutional groups have accelerated to support IoT interoperability. This paper plays out a far-reaching study on the cutting-edge answers for encouraging interoperability between various IoT stages. Likewise, the key difficulties in this theme are introduced

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study

Background Nintedanib slows lung function decline for patients with non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis (PPF) in clinical trials, but the real-world safety and efficacy are not known. Methods In this retrospective cohort study, standardised data were collected from patients in whom nintedanib was initiated for PPF between 2019 and 2020 through an early-access programme across eight centres in the United Kingdom. Rate of lung function change in the 12 months pre- and post-nintedanib initiation was the primary analysis. Symptoms, drug safety, tolerability and stratification by interstitial lung disease subtype and computed tomography pattern were secondary analyses. Results 126 patients were included; 67 (53%) females; mean±sd age 60±13 years. At initiation of nintedanib, mean forced vital capacity (FVC) was 1.87 L (58% predicted) and diffusing capacity of the lung for carbon monoxide (DLCO) was 32.7% predicted. 68% of patients were prescribed prednisolone (median dose 10 mg) and 69% were prescribed a steroid-sparing agent. In the 12 months after nintedanib initiation, lung function decline was significantly lower than in the preceding 12 months: FVC −88.8 mL versus −239.9 mL (p=0.004), and absolute decline in DLCO −2.1% versus −6.1% (p=0.004). Response to nintedanib was consistent in sensitivity and secondary analyses. 89 (71%) out of 126 patients reported side-effects, but 86 (80%) of the surviving 108 patients were still taking nintedanib at 12 months with patients reporting a reduced perception of symptom decline. There were no serious adverse events. Conclusion In PPF, the real-world efficacy of nintedanib replicated that of clinical trials, significantly attenuating lung function decline. Despite the severity of disease, nintedanib was safe and well tolerated in this real-world multicentre study

Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting.Methods 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability were collected via electronic survey.Results 24 UK prescribing centres responded to the service evaluation invitation. Between 17 November 2021 and 30 September 2022, 1120 patients received a multidisciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298 out of 1120, 26.6%), connective tissue disease associated ILD (197 out of 1120, 17.6%), rheumatoid arthritis associated ILD (180 out of 1120, 16.0%), idiopathic nonspecific interstitial pneumonia (125 out of 1120, 11.1%) and unclassifiable ILD (100 out of 1120, 8.9%). Of these, 54.4% (609 out of 1120) were receiving concomitant corticosteroids, 355 (31.7%) out of 1120 were receiving concomitant mycophenolate mofetil and 340 (30.3%) out of 1120 were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD.Conclusion We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study

Background Opportunities for home-monitoring are increasing exponentially. Home- spirometry is reproducible and reliable in interstitial lung disease (ILD), yet patients’ experiences are not reported. Given the morbidity and mortality associated with ILDs, maintaining health-related quality-of-life is vital. We report our findings from a codesigned, qualitative study capturing the perspectives and experiences of patients using home-spirometry in a UK regional ILD National Health Service England (NHSE) commissioned service.Methods Patients eligible for home-spirometry as routine clinical care, able to give consent and able to access a smart phone were invited to participate. In-depth, semistructured interviews were conducted at serial time points (baseline, 1, 3 and 6 months), recorded, transcribed and analysed thematically.Results We report on the experiences of 10 recruited patients (8 males; median age 66 years, range 50–82 years; 7 diagnosed with idiopathic pulmonary fibrosis, 3 other ILDs) who generally found spirometry convenient and easy to use, but their relationships with forced vital capacity results were complex. Main themes emerging were: (1) anticipated benefits—to identify change, trigger action and aid understanding of condition; (2) needs—clinical oversight and feedback, understanding of results, ownership, need for data and a need ‘to know’; (3) emotional impact—worry, reassurance, ambivalence/conflicting feelings, reminder of health issues, indifference; (4) ease of home-spirometry—simplicity, convenience and (5) difficulties with home-spirometry—technical issues, technique, physical effort.Conclusion Home-spirometry has many benefits, but in view of the potential risks to psychological well-being, must be considered on an individual basis. Informed consent and decision-making are essential and should be ongoing, acknowledging potential limitations as well as benefits. Healthcare support is vital

Real world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing interstitial lung disease (PF-ILD) and was recommended for this indication within the NHS in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting. Methods Twenty-six UK centres were invited to take part in a national service evaluation between 17/11/21 and 30/09/22. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability was collected via electronic survey. Results Twenty-four UK prescribing centres responded to the service evaluation invitation. Between 17/11/2021 and 30/09/2022, 1120 patients received a multi-disciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298/1120,26.6%), connective tissue disease associated interstitial lung disease (197/1120,17.6%), rheumatoid arthritis associated ILD (180/1120,16.0%), idiopathic non-specific interstitial pneumonia (125/1120,11.1%) and unclassifiable ILD (100/1120,8.9%). Of these, 54.4% (609/1120) were receiving concomitant corticosteroids, 355/1120 (31.7%) were receiving concomitant mycophenolate mofetil and 340/1120 (30.3%) were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD. Conclusion We have demonstrated the use of nintedanib for the treatment of PFILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting